DEADLINE TOMORROW: Berger Montague Advises Viatris (NASDAQ: VTRS) Investors to Inquire About a Securities Fraud Class Action by June 3, 2025

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors regarding the impact of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. FDA, leading to a significant drop in stock price following the announcement of disappointing financial results [1][3]. Company Overview - Viatris is a healthcare company based in Canonsburg, PA, supplying medicines to 1 billion patients globally [2]. Legal Proceedings - The lawsuit covers purchasers of Viatris securities from August 8, 2024, to February 26, 2025, and investors have until June 3, 2025, to seek appointment as lead plaintiff [1][2]. - The lawsuit claims that Viatris downplayed the consequences of regulatory issues, which were revealed when the company announced its Q4 and full-year 2024 financial results, resulting in a stock price decline of over 15% [3]. Financial Impact - Following the announcement on February 27, 2025, Viatris' stock price fell from $11.24 to $9.53 per share, a decrease of $1.71 per share [3].